Cell Therapy as Treatment for Cerebral Palsy

Neurogen Brain and Spine Institute

Overview

The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Cerebral Palsy

Interventions

Intrathecal autologous bone marrow mononuclear cell transplantationBIOLOGICAL

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosed cases of any type of Cerebral Palsy * age above 6 months. Exclusion Criteria: * presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/ Hepatitis C Virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[Hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia.

Locations (1)

Neurogen brain and spine institute

Navi Mumbai, Maharashtra, India

Outcomes

Primary Outcomes

change in clinical symptoms over a period of 2 years

Clinical symptoms such as oromotor skills, sitting and standing balance, speech, ambulation, muscle tone, cognition, hand and leg movement, walking, etc

Time frame: 2 years

Secondary Outcomes

Change in GMFM score

Time frame: 1 year

Change in Gross Motor Function Measure

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.